By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...